Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.
Authors: Dytfeld D; Poznan University of Medical Sciences, Poznan, Poland., Wróbel T; Wroclaw Medical University, Wroclaw, Poland., Jamroziak K; Medical University of Warsaw, Warsaw, Poland., Kubicki T; Poznan University of Medical Sciences, Poznan, Poland., Robak P; Medical University of Lodz, Lodz, Poland., Puła A; Medical University of Lodz, Lodz, Poland; University of Chicago, Chicago, IL, USA., Walter-Croneck A; Medical University of Lublin, Lublin, Poland; Department of Haematology and Bone Marrow Transplantation Centre of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland., Czyż J; Department of Haematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland., Tyczyńska A; Department of Haematology and Transplantology, Medical University of Gdansk, University Clinical Center Gdansk, Gdansk, Poland., Druzd-Sitek A; Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw, Poland., Giannopoulos K; Medical University of Lublin, Lublin, Poland., Nowicki A; Greater Poland Cancer Centre, Poznan, Poland., Szczepaniak T; Poznan University of Medical Sciences, Poznan, Poland; St James's Hospital, Dublin, Ireland., Łojko-Dankowska A; Poznan University of Medical Sciences, Poznan, Poland., Matuszak M; Poznan University of Medical Sciences, Poznan, Poland., Gil L; Poznan University of Medical Sciences, Poznan, Poland., Puła B; Institute of Haematology and Blood Transfusion, Warsaw, Poland; Department of Haematology, Medical University of Lodz, Lodz, Poland., Rybka J; Wroclaw Medical University, Wroclaw, Poland., Majcherek M; Wroclaw Medical University, Wroclaw, Poland., Usnarska-Zubkiewicz L; Wroclaw Medical University, Wroclaw, Poland., Szukalski Ł; Department of Haematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland., Końska A; Institute of Haematology and Blood Transfusion, Warsaw, Poland., Zaucha JM; Department of Haematology and Transplantology, Medical University of Gdansk, University Clinical Center Gdansk, Gdansk, Poland., Walewski J; Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw, Poland., Mikulski D; Medical University of Lodz, Lodz, Poland., Czabak O; Medical University of Lublin, Lublin, Poland., Robak T; Department of Haematology, Medical University of Lodz, Lodz, Poland., Lahoud OB; NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA; New York University Grossman School of Medicine, New York, NY, USA., Zonder JA; Wayne State University Karmanos Cancer Institute, Detroit, MI, USA., Cooperrider JH; University of Chicago, Chicago, IL, USA., Derman BA; University of Chicago, Chicago, IL, USA., Karrison T; University of Chicago, Chicago, IL, USA., Jakubowiak AJ; University of Chicago, Chicago, IL, USA. Electronic address: ajakubowiak@medicine.bsd.uchicago.edu.
Source: The Lancet. Haematology [Lancet Haematol] 2026 Apr; Vol. 13 (4), pp. e241-e253. Date of Electronic Publication: 2026 Mar 11.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Equivalence Trial; Comparative Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(26)00011-6